BiotechTube

MBX 2109

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypoparathyroidism

Conditions

Hypoparathyroidism

Trial Timeline

Aug 8, 2024 → Jun 4, 2025

NCT ID
NCT06465108

About MBX 2109

MBX 2109 is a phase 2 stage product being developed by MBX Biosciences for Hypoparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT06465108. Target conditions include Hypoparathyroidism.

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06465108Phase 2Completed

Competing Products

9 competing products in Hypoparathyroidism

See all competitors
ProductCompanyStageHype Score
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injectionMBX BiosciencesPhase 2
33
PCO371 + PlaceboChugai PharmaceuticalPhase 1
21
recombinant human somatotropinEli LillyPre-clinical
22
PalopegteriparatideAscendis PharmaPre-clinical
30
Palopegteriparatide (TransCon PTH)Ascendis PharmaPre-clinical
23
PalopegteriparatideAscendis PharmaPre-clinical
30
EnteraBio's Oral Parathyroid Hormone (1-34)Entera BioPhase 2
25
EBP05 + Forteo 0.02 mg + EBP11 + EBP22 + EBP11-F2 + EBP11-F4 + EBP11-F1 + EBP11-F5Entera BioPhase 1
19
EB612 (EBP05) + NATPARA/NATPAREntera BioPhase 2
25